See more : PT Eastparc Hotel Tbk (EAST.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Neurogene Inc. (NGNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurogene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xinjiang Goldwind Science & Technology Co., Ltd. (2208.HK) Income Statement Analysis – Financial Results
- SABB Takaful Company (8080.SR) Income Statement Analysis – Financial Results
- Olaplex Holdings, Inc. (OLPX) Income Statement Analysis – Financial Results
- True North Commercial Real Estate Investment Trust (TNT-UN.TO) Income Statement Analysis – Financial Results
- Opthea Limited (OPT.AX) Income Statement Analysis – Financial Results
Neurogene Inc. (NGNE)
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.26M | 3.20M | 2.28M | 1.82M | 340.00K | 0.00 | 0.00 | 0.00 | 0.00 | 135.95K | 59.57K | 130.78K | 125.60K |
| Gross Profit | -3.26M | -3.20M | -2.28M | -1.82M | -340.00K | 25.00M | 0.00 | 0.00 | 0.00 | -135.95K | -59.57K | -130.78K | -125.60K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.39M | 47.51M | 42.26M | 24.34M | 6.32M | 32.79M | 36.27M | 28.38M | 15.80M | 17.94M | 7.54M | 5.91M | 8.58M |
| General & Administrative | 11.19M | 9.01M | 8.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.19M | 9.01M | 8.27M | 15.39M | 17.79M | 15.74M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M | 1.73M |
| Other Expenses | -28.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 55.58M | 56.52M | 50.53M | 39.73M | 24.10M | 48.52M | 51.12M | 37.65M | 21.34M | 22.24M | 9.32M | 7.55M | 10.30M |
| Cost & Expenses | 55.58M | 56.52M | 50.53M | 41.55M | 24.44M | 48.52M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M | 10.43M |
| Interest Income | 2.95M | 1.34M | 17.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 10.80K | 19.75K |
| Interest Expense | 12.00K | 2.00K | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 2.25M | 42.92K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.30M | 3.20M | 2.28M | 1.82M | 340.00K | 0.00 | 1.00 | 1.00 | -421.00K | 135.95K | 59.57K | 130.78K | 125.60K |
| EBITDA | -52.29M | -51.99M | -49.59M | -31.46M | -69.10M | -31.58M | -50.18M | -37.00M | -21.76M | -21.65M | -8.63M | -7.54M | -10.54M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -55.58M | -56.52M | -50.53M | -41.55M | -24.44M | -23.52M | -51.12M | -37.65M | -21.34M | -22.38M | -9.38M | -7.68M | -10.43M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.27M | 1.33M | 17.00K | 8.28M | -45.00M | -8.06M | 936.00K | 643.00K | -520.00K | -1.65M | 641.24K | 9.11K | -232.21K |
| Income Before Tax | -36.32M | -55.19M | -50.52M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M | -10.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.00K | 17.00K | -1.00 | 168.14K | 0.00 | -1.00 | -1.00 | 0.00 | -222.00 | -5.04K | 42.29K | -154.47K |
| Net Income | -36.32M | -55.19M | -50.52M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -8.73M | -7.71M | -10.51M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.87 | -0.77 | -1.05 |
| EPS Diluted | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.87 | -0.77 | -1.05 |
| Weighted Avg Shares Out | 12.82M | 12.82M | 55.04M | 51.83M | 27.03M | 23.52M | 23.45M | 18.89M | 12.64M | 8.67M | 10.05M | 10.05M | 10.05M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.82M | 55.04M | 51.83M | 27.03M | 23.52M | 23.45M | 18.89M | 12.64M | 8.67M | 10.05M | 10.05M | 10.05M |
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and...
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the...
Neurogene to Participate in Upcoming Conferences
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Goldman Sachs 45th Annual Global...
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in...
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates. “We have made substantial...
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial...
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical...
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. “We...
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the expansion of its ongoing Phase 1/2 gene therapy clinical...
Neurogene to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following investor conferences:...
Source: https://incomestatements.info
Category: Stock Reports